Prognostic Factors for Postrelapse Survival after ex Vivo CD34+-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma-Reference-Cited by-同舟云学术

Prognostic Factors for Postrelapse Survival after ex Vivo CD34+-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma

Published:2020-11 Issue:11 Volume:26 Page:2040-2046
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Gomez-Arteaga Alexandra,Shah Gunjan L.,Baser Raymond E.,Scordo Michael,Ruiz Josel D.,Bryant Adam,Dahi Parastoo B.,Ghosh Arnab,Lahoud Oscar B.,Landau Heather J.,Landgren Ola,Shaffer Brian C.,Smith Eric L.,Koehne Guenther,Perales Miguel-Angel,Giralt Sergio A.,Chung David J.

Funder

National Cancer Institute

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference44 articles.

1. Allogeneic stem-cell transplantation for multiple myeloma: a systematic review and meta-analysis from 2007 to 2017;Yin;Cancer Cell Int,2018

2. Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life;Greil;Haematologica,2019

3. Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma;Maffini;Haematologica,2019

4. Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients;Kröger;Bone Marrow Transplant,2013

5. Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma;Giaccone;Blood,2011

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cellular Immunotherapies for Multiple Myeloma: Current Status, Challenges, and Future Directions;Oncology and Therapy;2022-02-01